Ligand pays $23M for royalty stake in pediatric myopia drug Ryjunea
Tweet Send to a Friend
Ligand Pharmaceuticals (Nasdaq: LGND) has acquired a royalty and milestone interest in Ryjunea, a pediatric myopia treatment marketed by Santen ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




